Immuneering | 8-K:Immuneering 公布 2024 年第一季度财务业绩并提供最新业务——报告了其 IMM-1-104 针对 RAS 突变实体瘤的 1/2a 期临床试验 1 期的积极业绩-
Immuneering | 10-Q:季度报表
Immuneering | DEFA14A:其他
Immuneering | DEF 14A:股东委托书决议
Immuneering | SC 13G/A:超过5%持股股东披露文件(修正)-Cormorant Asset Management, LP(5.81%),Bihua Chen(5.81%)等
Immuneering | SC 13G/A:超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(3.1%)
Immuneering | SC 13G/A:超过5%持股股东披露文件(修正)-BlackRock, Inc.(4.7%)
Immuneering | 4:持股变动声明-股东 Cormorant Asset Management, LP
Immuneering | SC 13G/A:超过5%持股股东披露文件(修正)-Merrin Investors LLC(9.46%)
Immuneering | 4:持股变动声明-董事 Schall Thomas J.
Immuneering | 4:持股变动声明-董事 Feinberg Peter
Immuneering | 4:持股变动声明-高管 Brakewood Harold Eugene
Immuneering | 4:持股变动声明-高管 Morales Mallory
Immuneering | 4:持股变动声明-高管 Neufeld Leah R
Immuneering | 4:持股变动声明-高管 Hall Brett Matthew
Immuneering | 4:持股变动声明-高管 Bookman Michael
Immuneering | 4:持股变动声明-董事 BERMAN ANN E
Immuneering | 4:持股变动声明-董事 Feinberg Peter
Immuneering | 4:持股变动声明-高管 Zeskind Benjamin J.
Immuneering | 4:持股变动声明-股东 Cormorant Asset Management, LP
暂无数据